Impax Laboratories Enters into Commercialization Agreement with Banner Pharmacaps

HAYWARD, Calif. & HIGH POINT, N.C.--(BUSINESS WIRE)-- Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it will collaborate with Banner Pharmacaps Inc. with respect to the supply and commercialization of two softgel capsule products. The products and terms of the agreement were not disclosed.

Larry Hsu, Ph.D., president and CEO of Impax Laboratories, said: “We are excited to collaborate with Banner, a global leader in developing and manufacturing softgel products. In less than a year, we have entered into four distinct partnerships for alternate dosage form products as we continue to execute our strategy of diversifying our product base. Our business development activities will continue to focus on delivering growth from high-value products, technologies, and businesses in complementary dosage forms.”

Roger E. Gordon, Ph.D., president and CEO of Banner Pharmacaps Inc., added: “We are delighted to be joining forces with Impax, a specialty pharmaceutical company whose vision and goals so closely mirror those of Banner. They join our expanding list of partners who look to Banner to provide expertise in the development of gelatin-based drug delivery systems and unique technology platforms.”

About Impax Laboratories, Inc.

Impax Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Impax markets its generic products through its Global Pharmaceuticals Division and markets third-party branded products through the Impax Pharmaceuticals Division. Additionally, where strategically appropriate, Impax has developed marketing partnerships to fully leverage its technology platform. Impax Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward, Philadelphia and Taiwan facilities. For more information, please visit the Company's Web site at: www.impaxlabs.com.

About Banner Pharmacaps Inc.

Banner Pharmacaps Inc. is a specialty pharmaceutical company dedicated to the research, development, and manufacturing of unique gelatin-based dosage forms. Banner has created proprietary drug delivery platforms that enhance and control the absorption of poorly soluble active pharmaceutical ingredients. Banner is building a portfolio of Rx and OTC products that utilize these innovative gelatin- and polymer-based technologies; and also actively seeks to develop and market products through strategic alliances and partnerships. Banner’s headquarters is located in High Point, North Carolina, with additional research labs and manufacturing facilities in The Netherlands, Canada, and Mexico. Additional information is available on the website www.banpharm.com.

The parent company of Banner Pharmacaps Inc. is VION N.V., an international food group. VION has annual sales of more than € 9 billion and employs 27,000 people worldwide. The VION head office is in Son, The Netherlands.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

To the extent any statements made in this news release contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the Company’s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the effect of current economic conditions on the Company’s industry, business, financial position and results of operations, the ability to maintain an effective system of internal control over financial reporting, fluctuations in revenues and operating income, the ability to successfully develop and commercialize pharmaceutical products, reductions or loss of business with any significant customer, the impact of competition, the ability to sustain profitability and positive cash flows, any delays or unanticipated expenses in connection with the operation of the Taiwan facility, the effect of foreign economic, political, legal and other risks on operations abroad, the uncertainty of patent litigation, consumer acceptance and demand for new pharmaceutical products, the difficulty of predicting Food and Drug Administration filings and approvals, the inexperience of the Company in conducting clinical trials and submitting new drug applications, the ability to successfully conduct clinical trials, reliance on alliance and collaboration agreements, the availability of raw materials, the ability to comply with legal and regulatory requirements governing the healthcare industry, the regulatory environment, the ability to protect the Company’s intellectual property, exposure to product liability claims and other risks described in the Company’s periodic reports filed with the Securities and Exchange Commission. Forward-looking statements speak only as to the date on which they are made, and Impax undertakes no obligation to update publicly or revise any forward-looking statement, regardless of whether new information becomes available, future developments occur or otherwise.



CONTACT:

Impax Laboratories, Inc.
Mark Donohue, 215-558-4526
Sr. Director, Investor Relations and Corporate Communications
www.impaxlabs.com
or
Banner Pharmacaps Inc.
Steve Sensoli, 336-812-7021
Executive Director, Global Business Development
[email protected]

KEYWORDS:   United States  North America  California  North Carolina

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health

MEDIA:

Logo
 Logo